ENCANTO Consortium Secures Full Regulatory Approval and Initiates Patient Recruitment
The ENCANTO Consortium today announced the successful achievement of full regulatory approval across all participating countries, a decisive step forward in advancing its pioneering clinical program.
With this approval, ENCANTO is now fully operational across Europe. Patient recruitment has already begun at two leading centers,University Hospital Basel (USB) and the Orthopaedic Hospital Vienna-Speising (OSS), demonstrating strong momentum and commitment from the consortium’s clinical partners. The first patient treatment is scheduled for 23 September 2025, marking the beginning of a new chapter in ENCANTO’s mission to deliver transformative solutions to patients.
“This achievement represents the strength of the ENCANTO partnership,” said Prof. Ivan Martin and Prof. Gianluca Vadalà. “Achieving full approval across all countries and already initiating recruitment is an extraordinary milestone. It reflects the urgency, dedication, and unity of our consortium as we prepare for the first patient treatment later this month.”